- Adults Ages 50 and over can be Vaccinated Against Shingles.
- Past Studies Show The Shingles Vaccine May Provide Additional Health Benefits.
- A New Study Found That People Who Reive the Shingles Vaccine Have 23% Lower Risk of Cardiovascular Events, With This Protective Benefit Lasting for Up to Eight Years after Vaccination.
Adults Ages 50 and Older Can Be Vaccinated Against Shingles. The Vaccine Provides More than
Past Studies Show That in Addition to Provide Protection Against Shingles, The Vaccine May Also Provide other Health Benefits, including to potentially Lower Risk for
“Shingles have traditionally been scarded as an infectious disease,” Sooji Lee, MD, Research in The Center for Digital Health in the Medical Science Research Institute at Kyung Hee University Medical Center in South Korea, Told Medical News Today.
“However, Previous Studies SuggestaD an Association Between Shingles and Chronic Conditions Such As Cardiovascular Disease. This Points to A Potential Link Between Infections and Chronic Design. Essential, ”She Explanred.
Read is the first author of a new study that has found People Who Receive The Shingles Vaccine Have 23% Lower Risk of Cardiovascular Events, Such as Heart Failure, Stroke, and Coronary Heart Disease, with This Protective Benefit Lasting for Up to Eight Years Post-Vaccation.
The Findings were Recently Published in the European Heart Journal.
SHINGLES VACCINE MAY LOWER RISK FOR ANY CARDIOVASCULAR EVENTS
For This Study, Refrachers Analyzed Medical Data from More than 1.2 Million Adults Ages 50 or Over Living in South Korea From 2012 Onward. Scientists Determined Whether or Not Participants prescribed a Live Zoster Vaccine For Shingles, Which Contains a Weakened Form of the Varicella-Zooster Virus.
At the Study’s Conclusion, Researchers Found That Participants Who Receive The Shingles Vaccine Had A 23% Lower Chance of Experiencing Any Cardiovascular Events, As Well As at 26% Lower Risk for Any Major Cardiovascular Event, Such As Stroke, Heart Attack, Or Death From Heart Disease.
Scientists Also Found that the Shingles Vaccine Lowered A person’s risk for heart failure by 26% and Coronary Heart Disease by 22%.
“The Finding That Vaccination was Associated With 23% Reduction in Cardiovascular Risk Even in A Previous Healthy Population Highlights The Potential of Shaingles Vaccination As a Preventive Measure Against Heart Disease,” Lee Said.
How the Vaccine Lowers Disease Risk
“SHINGLES CAN TRIGGER INFLAMMATION IN BLOOD VESSELS, POTENTIALLY LEADING TO CARDIOVASCULAR EVENTS. By Preventing the Shingles Infection, The Vaccine Likely Redes This Inflammatory Response, Thereby Lowering The Risk of Heart Disease.”
– Sooji Lee, MD
Vaccine’s Heart-Related Protection Last for Up to 8 Years
Additionionally, Lee and Her Team Found That the Cardiovascular Protective Effects of the Shingles Vaccine Last for As Long As Eight Years. And The Strongest Protection Occurred in the First Two to Three Years After Reviewing The Vaccine.
“This suggests that the Shingles Vaccine Provides A Long-Trm Protective Effect on Heart Health, With The Most Significant Benefits observed in the First Two to Three Years Post-Vaccation,” Lee Explanred. “Given that recombinant scam vaccines are Now More Widely Used and Have Shown Higher Effectiveness, Our Next Step is to Study Their Potential Impact On Cardiovascular Outcomes.”
“This is One of the Larest and Most Comprehensive Studies Following to Healthy General Population Over A PERIOD OF UP TO 12 YEARS, Dong Keon Yon, MD, PhD, Professor In The Department of Pediatrics and Digital Health at Kyung Hee University College of Medicine In South Korea, and Lead Author of The Study Says in a press release.
“For the first time, This has allowed US to examine the Association Between Shingles Vaccination and 18 Different Types of Cardiovascular Disease. We were Uble to Account for Various Other Health Conditions, Lifestyle Factors, and Socioeconomic Status, Making Our Findings More Robust.”
– Dong Keon Yon, MD, PHD
“However, as this study is based on an asian Cohort, The Results May Not Apply to All Populans,” Yon Continues. “While we driving Rigorous Analysis, This Study Does not establish a Causal Relationship, so potential bias from Other Underlying Factors Should Be Considered.”
Further Research in Other Demographics Needed
MNT Had the Opportunity To Speak With Cheng-Han Chen, MD, A Board Certified Insteentional Cardiologist and Medical Director of the Structural Heart Program at Memorialcare Saddleback Medical Center in Laguna Hills, CA, About This Study.
“BeSe Results Highlight the significant morbidity and mortality that is Associated with Shingles and Should Further Drive Our Efforts To Vaccinate As MANY Choose Patients As Possible,” Chen Commented.
“Varicella-ZoSter, The virus that causes short Varicella-JoSter Infection, Would Thus decrease cardiovascular risk by Preventing the adverse reactions associated with the virus. ”
-Cheng-Han Cen, MD
“The Varicella-ZoSter Can Cause Complications with Many Different Organ Systems, Including the Heart and Nervous System,” Chen Continued.
“Research on the Shingles Vaccine Can Help Utter Understand and Reduces The Health Effects of Varicella-JoSter Infection. This Study was performed, Specifically in an Asian Population. Further Research Will Be Need To Confirm Whether Added.
Observational Findings That Still Need Causal Research
MNT Also Spoke with Grant Simons, MD, Chief of Heart Rhythm Services at Hackensack University Medical Center in New Jersey, About This Research, Who Commented that he has found the results to be sumWhat Surprising, Though Not Entirely UNEXPECTED.
“While A Link Between Shingles and Cardiovascular Even Been Establish, The Extent of the Risk Reduction Associated With The Shingles Vaccine Shown in This Study is notable,” Simons Explanred.
“The Magnitude of the Risk Reduction (22-26%) Across VARIOVASCULAR EVENTS IS HIGHER THAN SOM MIGHT HAV ANTIPATED, WHICH IS SURPRISING. Previous Studies have suggested potential Benefit, but This Ver Long Study Provides Stronger Evidence and Quantifies The Potential The Potential Impacti DefiniteIly.
– Grant Simons, MD
“The Study Provides Comppelling Evidence for the Cardiovascular Benefits of the Shingles Vaccine, with a Stronger and Longer-Lasting Protective Effect Than Previous previous anticipated,” Simons Continued. “Although this is an observational Study, its Long Size is sumWhat Compony.
“However, it is important to note that more research is Needed to Fully Ecucidate The Specific Pathways Involved,” Simons Added. “This Study Provides Strong Observational Evidence For The Association, But Further Research is required to confirm and detail the causal mechalanisms.”
